【摘要】 目的 探讨可降解药物支架对冠心病患者血浆可溶性CD40配体的影响。 方法 对100例接受裸支架（BMS组）和100例接受可降解药物支架治疗（EXCEL支架组）的冠心病患者进行冠状动脉造影随诊。测定术后1 mo、3 mo、6 mo末血浆可溶性CD40配体水平。 结果 两组患者一般资料无显著性差异（P＞0.05）。BMS组术后1 mo、3 mo、6 mo末血浆可溶性CD40配体水平均显著高于EXCEL支架组（P均＜0.01）；术后6 mo冠状动脉造影支架内再狭窄发生率显著高于EXCEL支架组（P＜0.01），晚期支架内血栓发生率无显著差异（P＞0.05）。 结论 可降解药物支架能降低血浆可溶性CD40配体水平，适度内皮化，减少再狭窄，减少迟发性血栓形成。
【关键词】 冠心病；血浆可溶性CD40；CD40配体；EXCEL支架
【Abstract】 Objective To explore the effects of degradable drug support on soluble CD40 ligand of patients with coronary heart disease（CHD）. Methods Coronary arteriongraphy followups were conducted in 100 CHD patients receiving bare support（BMS group） and 100 ones doing EXCEL support（EXCEL group）. Plasma CD40 ligand levels were measures at the end of the 1st，3rd and 6th month after operation. Results There was no significant difference in general data between the 2 groups（P>0.05）. At the ends of the 1st，3rd and 6th month after operation，plasma CD40 ligand levels were significantly higher in the BMS than in the EXCEL group（P<0.01）. In the 6th month after operation，intrasupport rectenosis incidence was significantly higher in the BMS than in the EXCEL group（P<0.01），and there was no difference in the incidence of advancedstage intrasuppor……
<<<<<全文未完，本文约1977个中文字，未计算英文字母、数字>>>>>
